Patents Examined by Hazel F. Sidberry
-
Patent number: 5641492Abstract: A combination vaccine, with methods of preparation and treatment, for protection against Gram negative bacterial diseases. The vaccine includes a killed suspension of a bacterial mutant from the taxonomic family Enterobacteriaceae, a B-lymphocyte proliferating immune modulator, and a protein and lipid binding adjuvant. A hyperimmune serum for treating diseased animals is prepared by vaccinating a donor animal with the combination vaccine and then preparing clot serum containing antigen specific antibodies. The mutant is ATCC No. 53000 and is produced by ionizing radiation of Salmonella enteritidis. The immune modulator is a detoxified extract of lipopolysaccharide and is useful with many antigens to enhance primary immune response.Type: GrantFiled: September 27, 1993Date of Patent: June 24, 1997Assignee: The Curators of the University of MissouriInventors: Ronald F. Sprouse, Harold E. Garner
-
Patent number: 5641874Abstract: A purified, isolated DNA sequence encoding human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.Type: GrantFiled: January 22, 1993Date of Patent: June 24, 1997Assignee: New York UniversityInventors: Peter Elsbach, Jerrold Weiss
-
Patent number: 5639876Abstract: The present invention relates to isolated parasitic helminth nucleic acid sequences capable of hybridizing, under stringent conditions, to at least a portion of D. immitis nucleic acid sequence p4 and/or to at least a portion of D. immitis nucleic acid sequence p22U; to isolated parasitic helminth proteins that are encoded by such parasitic helminth nucleic acid sequences and that are capable of selectively binding to at least one component of immune serum capable of inhibiting helminth development; and to antibodies raised against such isolated parasitic helminth proteins. The present invention also relates to therapeutic compositions comprising such isolated nucleic acid sequences, proteins and/or antibodies. The present invention also includes methods to produce and use such nucleic acids, proteins, antibodies and therapeutic compositions capable of protecting animals from parasitic helminth infection and, particularly, from heartworm infection.Type: GrantFiled: August 19, 1993Date of Patent: June 17, 1997Assignees: Heska Corporation, Colorado State University Research FoundationInventors: Cynthia Ann Tripp, Glenn Robert Frank, Robert B. Grieve
-
Patent number: 5635596Abstract: Peptides derived from the pS2 protein and polyclonal and monoclonal antibodies directed against pS2 and against pS2 fragments. Method of obtaining the secreted from of the pS2 protein and fragments thereof. Method of detecting and diagnosing different pathological conditions and especially hormone-dependent breast cancers and pathological conditions of the stomach.Type: GrantFiled: December 10, 1992Date of Patent: June 3, 1997Assignee: AderegemInventors: Pierre Chambon, Marie-Christine nee Martinet Rio, Jean-Pierre Bellocq
-
Patent number: 5624905Abstract: This invention provides a purified protein, having an apparent molecular weight of about 800 kDa, designated merosin. Also provided is an isolated nucleic acid sequence which encodes merosin. The invention further provides antibodies, vectors, and the expression of recombinant proteins by use of a host vector system. The invention also provides the use of merosin to promote neurite growth and for certain diagnostic applications.Type: GrantFiled: February 23, 1995Date of Patent: April 29, 1997Assignee: La Jolla Cancer Research FoundationInventors: Eva Engvall, Ilmo Leivo
-
Patent number: 5622706Abstract: The cloning and sequencing of the gene which codes for a new pilinic subunit of Bordetella pertussis are described. The aminoacid sequence of the mature subunit, deduced from its necleotide sequence, is similar but not identical to that of the known pilins 2, 3 and 6. Polypeptides having the aminoacid sequence of the mature pilinic subunit or of regions thereof are particularly useful for the development of synthetic acellular vaccines against pertussis.Type: GrantFiled: November 4, 1994Date of Patent: April 22, 1997Assignees: Sclavo S.p.A., Eniricerche S.p.A.Inventors: Paola Pedroni, Barbara Riboli, Francesca De Ferra, Guido Grandi, Salvatore Toma, Beatrice Arico, Rino Rappuoli
-
Patent number: 5616329Abstract: A method is described for preparing an antigenic product which incorporates exposing an aerosol of a microbial suspension to temperatures at which substantially only the heat stable components of the microbial suspension which retain their immunogenic properties remain. More specifically, the aerosol is exposed to an elevated temperature which denatures all labile components and removes the liquid portion of the aerosol by evaporation.Type: GrantFiled: July 5, 1994Date of Patent: April 1, 1997Assignee: Microtek Research and Development Ltd.Inventors: Stephen G. Newman, William W. Kay
-
Patent number: 5603938Abstract: High molecular weight surface proteins of non-typeable Haemophilus inflenzae which exhibit immunogenic properties and genes encoding the same are described. Specifically, genes coding for two immunodominant high molecular weight proteins, HMW1 and HMW2, have been cloned, expressed and sequenced, while genes coding for high molecular proteins HMW3 and HMW4 have been cloned, expressed and partially sequenced.Type: GrantFiled: October 5, 1994Date of Patent: February 18, 1997Assignees: St. Louis University, Washington UniversityInventor: Stephen J. Barenkamp
-
Patent number: 5593679Abstract: The present invention is concerned with vaccines effective in protecting poultry against E. coli septicaemia, which contain or can cause the production of fimbriae of the F11 type or an immunogenic section thereof, or antibodies against these.Type: GrantFiled: April 5, 1994Date of Patent: January 14, 1997Assignee: Akzo Nobel N.V.Inventor: Johannes F. van den Bosch
-
Patent number: 5585102Abstract: This invention relates to flagella-less strains of Borrelia to novel methods for use of the microorganisms as vaccines and in diagnostic assays. Although a preferred embodiment of the invention is directed to Borrelia burgdorferi, the present invention encompasses flagella-less strains of other microorganisms belonging to the genus Borrelia. Accordingly, with the aid of the disclosure, flagella-less mutants of other Borrelia species, e.g., B. coriacei, which causes epidemic bovine abortion, B. anserina, which causes avian spirochetosis, and B. recurrentis and other Borrelia species causative of relapsing fever, such as Borrelia hermsii, Borrelia turicatae, Borrelia duttoni, Borrelia persica, and Borrelia hispanica, can be prepared and used in accordance with the present invention and are within the scope of the invention. Therefore, a preferred embodiment comprises a composition of matter comprising a substantially pure preparation of a strain of a flagella-less microorganism belonging to the genus Borrelia.Type: GrantFiled: September 20, 1993Date of Patent: December 17, 1996Assignee: Board of Regents, The University of Texas SystemInventors: Alan G. Barbour, Virgilio G. Bundoc, Adriadna Sadziene
-
Patent number: 5571694Abstract: Expression of tetanus toxin fragment C is accomplished employing a DNA coding sequence having a (G+C)-content that has been increased in the region from nucleotide 410 to the 3' end of the coding sequence relative to the wild-type DNA sequence. This allows the production of complete mRNA transcripts. Typically the (G+C)-content is increased in the following regions: (i) nucleotides 510-710, (ii) nucleotides 650-850, (iii) nucleotides 800-1100, (iv) nucleotides 900-1200 and (v) nucleotides 1100-1356. These regions in wild-type DNA encompass terminator sequences.Type: GrantFiled: July 25, 1994Date of Patent: November 5, 1996Assignee: Evans Medical LimitedInventors: Andrew J. Makoff, Michael A. Romanos, Jeffrey J. Clare, Neil F. Fairweather
-
Patent number: 5558869Abstract: Peanut allergen Ara h II was identified using the sera of patients who had atopic dermatitis and a positive food challenge to peanut. The Ara h II allergen, having a molecular weight of 17 kD and a pI of 5.2, was isolated by anion exchange chromatography. Ara h II may be used to detect and quantify peanut allergens in foodstuffs.Type: GrantFiled: November 29, 1993Date of Patent: September 24, 1996Assignee: University of ArkansasInventors: A. Wesley Burks, Jr., Ricki M. Helm
-
Patent number: 5554371Abstract: A highly-antigenic, recombinant polypeptide of a molecular weight of about 110-kD by SDS-PAGE is disclosed, which is derived by transforming E. coli with a 7.1 kB DNA fragment from EcoR1-digested B. burgdorferi DNA, followed by identification of cloned transformants expressing polypeptides which bind to anti-B. burgdorferi antibodies.Type: GrantFiled: April 14, 1994Date of Patent: September 10, 1996Assignee: Regents of the University of MinnesotaInventors: Anthony C. Caputa, Russell F. Bey, Michael P. Murtaugh
-
Patent number: 5552146Abstract: The present disclosure relates to selected antigenic proteins obtained from the outer membranes of Moraxella catarrhalis, that have been found by the inventors to have a variety of useful properties. These proteins, termed OMPs ("Outer Membrane Proteins"), are characterized as having molecular weights of 30, 80 and 100 kD, respectively. Studies set forth herein demonstrate that monoclonal antibodies directed against these proteins confer a protective effect against infection by Moraxella catarrhalis organisms in animal models, demonstrating the potential usefulness of such antibodies in conferring passive immunity as well as the potential usefulness of these OMPs, or variants thereof, in the preparation of vaccines. Also disclosed are DNA segments encoding these OMPs, methods for preparing the antigens, or variants, through the application of recombinant DNA techniques, as well as diagnostic methods and embodiments.Type: GrantFiled: August 15, 1991Date of Patent: September 3, 1996Assignee: Board of Regents, The University of Texas SystemInventors: Eric J. Hansen, Merja Helminen, Isobel Maciver
-
Patent number: 5549898Abstract: A purified antigenic surface protein of Anaplasma marginale has been identified, and is capable of inducing immune responses in ruminants which neutralizes virulent Anaplasma marginale. The antigenic surface protein has a molecular weight of about 105,000 daltons, and can be purified by an immunoaffinity chromatography process. The antigen has further utility in diagnostic tests for anaplasmosis. It can be synthesized by polypeptide procedures or by genetic engineering. DNA and amino acid sequences have been developed for the antigen according to this invention. The antigen is useful as a vaccine component for protecting mammals against infection by Anaplasma marginale and may be useful for rickettsial organisms other than Anaplasma marginale.Type: GrantFiled: April 15, 1994Date of Patent: August 27, 1996Inventors: Travis C. McGuire, Guy H. Palmer, Anthony F. Barbet, William C. Davis
-
Patent number: 5547931Abstract: The invention provides methods for stimulating thrombocytopoiesis and for treating thrombocytopenia in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein (mCRP).Type: GrantFiled: February 23, 1994Date of Patent: August 20, 1996Assignee: Immtech International Inc.Inventor: Lawrence A. Potempa
-
Patent number: 5538727Abstract: Anti-cholesterolemic eggs are disclosed, said eggs being obtained from animals hyperimmunized against at least one anti-cholesterolemic antigen. A vaccine producing said anti-cholesterolemic egg is disclosed, said vaccine comprising at least one anti-cholesterolemic antigen. Further, a dietary supplement for humans and other animals which does not elevate serum lipid concentrations is disclosed, said supplement comprising the anti-cholesterolemic eggs or fractions thereof. A method for treating vascular disorders in humans and other animals is also disclosed which comprises administering to said subjects said anti-cholesterolemic eggs for a time and in amounts sufficient to produce anti-arteriosclerotic effects, anti-aging vascular effects, and/or serum lipid-lowering effects.Type: GrantFiled: June 10, 1992Date of Patent: July 23, 1996Assignee: DCV Biologics, L.P.Inventors: Ralph J. Stolle, Lee R. Beck
-
Patent number: 5536658Abstract: The present invention provides a chondroitinase attenuated Edwardsiella ictaluri bacteria. Further, this invention provides a vaccine comprising a protective amount of a chondroitinase attenuated strain of Edwardsiella ictduri bacteria and a method for protecting a fish from Enteric Septicemia comprising administering the vaccine to the fish.Type: GrantFiled: October 23, 1992Date of Patent: July 16, 1996Assignee: The University of Georgia Research FoundationInventors: Emmett B. Shotts, Jr., Richard K Cooper, II
-
Patent number: 5536496Abstract: This invention provides vaccine compositions, methods of producing same and methods for protecting porcine animals against disease associated with infection by toxigenic Pasteurella multocida. The vaccines of this invention contain effective amounts of a free, soluble P. multocida toxoid and/or a P. multocida bacterin with a cell-bound toxoid.Type: GrantFiled: May 12, 1995Date of Patent: July 16, 1996Assignee: Pfizer Inc.Inventors: Joseph C. Frantz, David S. Roberts, Leroy A. Swearingin, Richard J. Kemmy
-
Patent number: 5536497Abstract: Polypeptides related to fimbriae of Porphyromonas gingivalis are described and claimed which exhibit inhibition of bacterial adhesion to saliva-coated surfaces. The polypeptides are selected from the group consisting of fimbriae, fimbrillin, and fimbrial-related. peptides derived therefrom. The polypeptides are used as active ingredients in various oral formulations designed to prevent adhesion of P. gingivalis to host mucosal surfaces and thus interfering with the development of periodontitis. The polypeptides are also used in subunit vaccine formulations for use against pathogenic, fimbriated P. gingivalis in the prophylactic treatment of periodontitis. Use of the polypeptides for inducing protective immunity in serum and gingival crevicular fluid may prevent primary infection with P. gingivalis as well as the spread of the organism between intraoral reservoirs.Type: GrantFiled: December 21, 1992Date of Patent: July 16, 1996Assignee: The Research Foundation of State University of New YorkInventors: Richard T. Evans, Gurrinder S. Bedi, Robert J. Genco, Hakimuddin T. Sojar